• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Education
  • Events
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Astra Zeneca sign deal to commercialise Oxford COVID-19 vaccine

18th May 2020 by PIP editor Leave a Comment

 

UK’s top researchers rapidly working to find a coronavirus vaccine will benefit from £84 million of new government funding, Business Secretary Alok Sharma has announced.

 

The funding comes as Oxford University agrees on a global licensing agreement with AstraZeneca, the UK-based pharmaceutical company, for the commercialisation and manufacturing of their potential vaccine.

 

This means that, if the Oxford vaccine is successful, AstraZeneca will work to make up to 30 million doses available by September for people in the UK, as part of an agreement to deliver 100 million doses in total.

 

This will mean the UK will be the first country to get access to the vaccine, should it be successful.

 

Business Secretary Alok Sharma said:

 

“Our scientists are at the forefront of vaccine development. This deal with AstraZeneca means that if the Oxford University vaccine works, people in the UK will get the first access to it, helping to protect thousands of lives.

 

“The agreement will deliver 100 million doses in total, ensuring that in addition to supporting our own people, we are able to make the vaccines available to developing countries at the lowest possible cost.

 

“The UK continues to lead the global response to find a vaccine, and the government is backing our scientists to do this as quickly as possible.”

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

 

“AstraZeneca is at the forefront of the response to COVID-19, and we are proud to be working with Oxford University to help make this vaccine available as quickly as possible. I would like to thank HM Government for its commitment to the vaccine and welcome its leadership and generosity for its help in expanding access beyond the UK. Our company is working hard to establish parallel supply agreements with other nations and multilateral organisations to ensure fair and equitable access around the world.”

 

Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said:

 

“The University of Oxford is immensely proud of the scientists at the Jenner Institute and the Oxford Vaccine Group who have worked tirelessly to discover and develop this vaccine in record time. We now have a partner in AstraZeneca who are ideally positioned to help us evaluate the vaccine, manufacture it and distribute it to UK citizens as well as to the rest of the world. They share our commitment to true global access to end this pandemic.”

 

Professor Robin Shattock of Imperial College London said:

 

“This funding will greatly accelerate our efforts to demonstrate the effectiveness of our vaccine and make it available to at risk populations as rapidly as possible. Access to such support allows us to move at unprecedented speed.”

 

 

This circular is being shared under the Open Government Copyright licence.

 

Share this:

  • Tweet
  • WhatsApp
  • Telegram
  • Email

Related

Next article  GPhC say assessment is an 'essential step' towards registration

Filed Under: News Tagged With: Astra Zeneca, Vaccine

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Resitters: The forgotten pre-registration pharmacist cohort

Is a pharmacist who sells rapid antibody tests unfit to practise?

All over the counter opiates should be made prescription only

Pharmacists are disillusioned, disenfranchised and marginalised

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.